XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Note 6 - Goodwill and Intangible Assets, Net
3 Months Ended
Jun. 30, 2023
Notes to Financial Statements  
Goodwill and Intangible Assets Disclosure [Text Block]

Note 6. Goodwill and Intangible Assets, Net

 

Intangible assets, the significant majority of which are finite-lived, consisted of the following:

 

   

June 30, 2023

   

March 31, 2023

 
   

Gross Carrying Amount

   

Accumulated Amortization

   

Net Carrying Amount

   

Gross Carrying Amount

   

Accumulated Amortization

   

Net Carrying Amount

 

Customer relationships

  $ 232,431     $ (89,916 )   $ 142,515     $ 238,247     $ (86,058 )   $ 152,189  

Intellectual property

    66,629       (21,342 )     45,287       65,950       (19,550 )     46,400  

Other intangibles

    24,486       (6,894 )     17,592       24,793       (6,567 )     18,226  

Total

  $ 323,546     $ (118,152 )   $ 205,394     $ 328,990     $ (112,175 )   $ 216,815  

 

Amortization expense for finite-lived intangible assets acquired in a business combination was as follows:

 

   

Three Months Ended June 30,

 
   

2023

   

2022

 

Amortization in cost of revenues

  $ 1,728     $ 1,708  

Amortization in general and administrative

    5,492       5,612  

Total

  $ 7,220     $ 7,320  

For the following fiscal years ending March 31, amortization expense is estimated as follows:

 

Remainder of 2024

 

$ 21,017

 

2025

 

26,612

 

2026

 

25,847

 

2027

 

25,346

 

2028

 

24,890

 

 

The change in the carrying amount of goodwill was as follows:

 

   

Sterilization and Disinfection Control

   

Clinical Genomics

   

Biopharmaceutical Development

   

Calibration Solutions

   

Total

 

March 31, 2023

  $ 29,559     $ 135,811     $ 83,857     $ 37,217       286,444  

Effect of foreign currency translation

    (12 )     (138 )     (3,376 )     (3 )     (3,529 )

Measurement period adjustment - Belyntic Acquisition

    -       -       841       -       841  

June 30, 2023

  $ 29,547     $ 135,673     $ 81,322     $ 37,214     $ 283,756  

 

Goodwill in the Biopharmaceutical Development division related to the Belyntic acquisition and is tax deductible.